1 year return (CAGR)
-3.03%
iShares eb.rexx Government Germany UCITS ETF (DE) Exchange (F, EUR)
EXHA.F
120.79
-0.07 (-0.06%)
F
Loading...
3 year return (CAGR)
-
5 year return (CAGR)
-
10 year return (CAGR)
-
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
-
Price/Sales
-
Ent value
-
Price/Book
-
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 121.01 |
| Daily high | 121.57 |
| Daily low | 120.79 |
| Daily Volume | 0K |
| All-time high | 147.47 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| EXHA.F | S&P500 | |
| Current price drop from All-time high | -18.09% | -0.39% |
| Highest price drop | -18.81% | -56.47% |
| Date of highest drop | 28 Sep 2026 | 9 Mar 2009 |
| Avg drop from high | -15.95% | -10.67% |
| Avg time to new high | - | 12 days |
| Max time to new high | 503 days | 1805 days |
News
Suominen Corporation’s stock exchange release on October 9, 2026, at 11:00 a.m. (EEST) Suominen Corporation will publish its financial reports in 2027 as follows: March 2, 2027 – Financial Statements ...
October 9, 2026
Investing.com -- Barclays downgraded Ryanair and Norwegian Air Shuttle to Equal Weight from Overweight, saying persistently high fuel prices threaten fourth-quarter and 2027 profits across European ai...
October 9, 2026
Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response.
October 8, 2026
Argenx says it discontinued a late-stage clinical trial in patients with Sjögren’s disease at the recommendation of an independent committee.
October 8, 2026
INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF SEPTEMBER 30, 20261 Paris – October 8, 2026 NUMBER OF SHARES AS OF SEPTEMBER 30, 2026 Date09/30/2026Company nameKlépierre...
October 8, 2026
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
October 8, 2026
Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective.Dublin, Oct. ...
October 8, 2026
VIENNA, AUSTRIA - October 7, 2026 (NEWMEDIAWIRE) - The Supervisory Board of VERBUND AG today appointed Stefan Waldner (49) as Chief Financial Officer (CFO) and a member of the Management Board. His ap...
October 7, 2026
Novartis (SWX:NOVN) just put multiple sclerosis front and center for investors, flagging 46 abstracts for MSToronto2026, including late breaking Phase III REMODEL data on remibrutinib and new Kesimpta...
October 7, 2026
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 1.2% and the
October 7, 2026